$BHVN Biohaven will present safety and IgG lowering data from its ongoing single ascending dose (SAD) study of BHV-1300 at the company's annual R&D day at the Yale Innovation Summit in New Haven, Connecticut on May 29, 2024. The presentation is part of the first-in-human data from the BHV-1300 IgG protein degrader program, which has been delayed. Analysts are particularly interested in the study's profile and efficacy.
This is the context for those want to do the SAD comps w/ the pending $BHVN IgG data vs those from $IMVT and $ARGX -.. For SAD readouts, I care the most on the unexpected events, esp. tox - then obviously the pk parameters - to me - SAD in P1 is a great screen for unexpected… https://t.co/Czws2mhm1D
$BHVN ( $IMVT ) The anatomy of a SAD readout? BHV-1300 first in human readout date has gone from: - “1Q 2024” in the current corporate deck to - “Late 1Q/early 2Q” in 2/29 PR for earnings call to - May 29, 2024 — at company IR day, via a Saturday PR… Given the… https://t.co/AWM7tdlcsd https://t.co/Qu1Ro2G4sh
This is one clin trial readout I am very curious about - in 2H24 - https://t.co/IwTDzStmQw - INV-202 P2 in Obesity population - .. does it work, how well it works, any AEs - and chance to combo with existing options - and potential for synergy (either in weight loss #s or able…
My general take on the $BHVN updated PR - 1) IgG side - met expectations or else they don't need to mention it first in the PR list and present it at the important R&D day - .. that said, it's a SAD study - so the key data I worry on the downside been - profile not as robust as…
$BHVN will present first-in-human data from its BHV-1300 IgG protein degrader program on May 29 at an R&D day. https://t.co/iHIXskpNRr This unveil is later than expected. Not sure what to read into that, if anything. I wrote a brief preview of -1300 in my newsletter this…
$BHVN IgG data presentation at its annual R&D day in May 29 - OCD P3 continues post interim look - .. https://t.co/0PwyyOTX7g https://t.co/ZbIHK1dbfv
$BHVN Biohaven announces it will present safety and IgG lowering data from its ongoing single ascending dose (SAD) study of BHV-1300 at the company's annual R&D day at the Yale Innovation Summit in New Haven, Connecticut on May 29, 2024 https://t.co/Bl0i72wPxF